- Collaboration aligns with Immuneering’s expanding strategy to provide a broad population of cancer patients with a wide set of treatment options -

- Represents Immuneering’s fourth agreement with a pharma partner -

- Further expands external partnerships to bring innovative new combinations to patients -
 

NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX) today announced it has entered into a clinical trial collaboration and supply agreement with Astellas Pharma Global Development, Inc., a subsidiary of Astellas Pharma Inc. (TSE: 4503). Under the agreement, Immuneering will supply its investigational MEK inhibitor, atebimetinib, for two Astellas-sponsored studies targeting the subset of pancreatic cancer patients whose tumors express CLDN18.2. One trial will evaluate an Astellas investigational CLDN18.2-targeted program added to atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in first-line metastatic pancreatic cancer patients. A second trial will evaluate a chemotherapy-free regimen combining a different Astellas investigational CLDN18.2-targeted program with atebimetinib in previously-treated metastatic pancreatic cancer patients. Further trial details will be forthcoming.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.